The safety of over-the-counter niacin. A randomized placebo-controlled trial [ISRCTN18054903] (Q24797790)

1

object named as

Edward Mills

0 references

author name string

Jonathan Prousky

2

0 references

Gannady Raskin

3

0 references

Joel Gagnier

4

0 references

Beth Rachlis

5

0 references

David Juurlink

BMC Clinical Pharmacology

7

0 references

language of work or name

English

0 references

publication date

13 November 2003

0 references

published in

0 references

volume

3

0 references

issue

1

0 references

page(s)

4

0 references

cites work

Incomplete evidence: the inadequacy of databases in tracing published adverse drug reactions in clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=280687

Release of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acid

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=280687

Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=280687

Niacin-ER and lovastatin treatment of hypercholesterolemia and mixed dyslipidemia

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=280687

Adverse drug reactions: keeping up to date

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=280687

Attitudinal survey of voluntary reporting of adverse drug reactions

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=280687

Different standards for reporting ADRs to herbal remedies and conventional OTC medicines: face-to-face interviews with 515 users of herbal remedies.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=280687

Effect of two aspirin pretreatment regimens on niacin-induced cutaneous reactions

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=280687

A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=280687

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=280687

Nicotinic acid-induced fulminant hepatic failure

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=280687

Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia

30 May 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6904-3-4

Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6904-3-4

Niacin-simvastatin combination benefits patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6904-3-4

Risks associated with herbal medicinal products.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6904-3-4

Drug companies should report side effects in terms of frequency

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6904-3-4

Beneficial effects of rosuvastatin alone and in combination with extended-release niacin in patients with a combined hyperlipidemia and low high-density lipoprotein cholesterol levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6904-3-4

Low-Dose Aspirin and Ibuprofen Reduce the Cutaneous Reactions Following Niacin Administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6904-3-4

Reporting of Adverse Effects in Clinical Trials Should Be Improved

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6904-3-4

Physicians' attitudes towards voluntary reporting of adverse drug events

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6904-3-4

21 January 2018

Improving ADR reporting

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/14614780

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Folate reduces homocysteine levels and lowers rate of restenosis

1 reference

https://api.crossref.org/works/10.1186%2F1472-6904-3-4

inferred from DOI database lookup

7 January 2021

based on heuristic

First AbioCor trial patient dies

1 reference

https://api.crossref.org/works/10.1186%2F1472-6904-3-4

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1186/1472-6904-3-4

1 reference

Dimensions Publication ID

1 reference

9 September 2019

https://scigraph.springernature.com/pub.10.1186/1472-6904-3-4

1 reference

1 reference

PubMed publication ID

14614780

1 reference